Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed or Refractory B-cell Non-hodgkin Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT05326243
What this trial is testing

Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma

Who this might be right for
Diffuse Large B Cell LymphomaPrimary Mediastinal Large B Cell LymphomaLarge B-cell Lymphoma+2 more
Pell Bio-Med Technology Co., Ltd. 49
Early research (Phase 1)Ended earlyNCT01678443
What this trial is testing

Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies

Who this might be right for
Adult Nasal Type Extranodal NK/T-cell LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell Lymphoma+30 more
Fred Hutchinson Cancer Center 2
Testing effectiveness (Phase 2)WithdrawnNCT00003663
What this trial is testing

Rituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Hoag Memorial Hospital Presbyterian
Testing effectiveness (Phase 2)Study completedNCT00220285
What this trial is testing

Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkin's LymphomaLymphoma, B-CellLymphoma, Low-Grade
Bayer 45
Testing effectiveness (Phase 2)UnknownNCT04553393
What this trial is testing

Decitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor Burden

Who this might be right for
Refractory or Relapsed Aggressive r/r B-NHL With Huge Tumor Burden
Chinese PLA General Hospital 80
Very early researchStudy completedNCT02405078
What this trial is testing

Tumor-Specific Clonotype, Metabolic Profile, and PET/CT in Predicting Chemotherapy Response in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Who this might be right for
Recurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma
M.D. Anderson Cancer Center 35
Early research (Phase 1)Study completedNCT01290549
What this trial is testing

Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma

Who this might be right for
Non-Hodgkins LymphomaChronic Lymphocytic Leukemia
Genentech, Inc. 95
Testing effectiveness (Phase 2)UnknownNCT00014664
What this trial is testing

Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
PDL BioPharma, Inc.
Testing effectiveness (Phase 2)Active Not RecruitingNCT04416984
What this trial is testing

Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

Who this might be right for
Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
Allogene Therapeutics 160
Early research (Phase 1)Study completedNCT02746952
What this trial is testing

Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia

Who this might be right for
B-cell Acute Lymphoblastic Leukemia
Institut de Recherches Internationales Servier 25
Testing effectiveness (Phase 2)Ended earlyNCT04082936
What this trial is testing

Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma

Who this might be right for
Non-Hodgkin LymphomaFollicular LymphomaDLBCL+2 more
IGM Biosciences, Inc. 97
Testing effectiveness (Phase 2)WithdrawnNCT05365100
What this trial is testing

BN102 in Patients With Previously Treated CLL/SLL and B-cell NHL

Who this might be right for
CLL/SLLNHL
BioNova Pharmaceuticals (Shanghai) LTD.
Large-scale testing (Phase 3)WithdrawnNCT00551239
What this trial is testing

Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

Who this might be right for
LeukemiaLymphoma
CTI BioPharma
Very early researchUnknownNCT04639739
What this trial is testing

Anti-CD19 CAR NK Cell Therapy for R/R Non-Hodgkin Lymphoma.

Who this might be right for
NHL
Xinqiao Hospital of Chongqing 9
Testing effectiveness (Phase 2)Looking for participantsNCT05554939
What this trial is testing

Allogenic CD19-targeting CAR-γδT Cell Therapy in R/R NHL

Who this might be right for
Non Hodgkin's Lymphoma
Chinese PLA General Hospital 30
Early research (Phase 1)UnknownNCT04296461
What this trial is testing

Study of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-cell Lymphoma

Who this might be right for
B-cell Non-Hodgkin Lymphoma
UWELL Biopharma 20
Large-scale testing (Phase 3)Ended earlyNCT02951156
What this trial is testing

Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

Who this might be right for
Diffuse Large B-Cell Lymphoma
Pfizer 29
Not applicableNot Yet RecruitingNCT07637929
What this trial is testing

Non-Interventional Study of Puzol-cel for CD19-Positive Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Who this might be right for
Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (r/r B-ALL)
Chongqing Precision Biotech Co., Ltd 200
Not applicableStudy completedNCT00053157
What this trial is testing

Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia

Who this might be right for
Chronic Myeloproliferative DisordersGraft Versus Host DiseaseLeukemia+3 more
Roswell Park Cancer Institute 10
Large-scale testing (Phase 3)Study completedNCT04833114
What this trial is testing

Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)

Who this might be right for
Relapsed Diffuse Large B-cell LymphomaRefractory Diffuse Large B-Cell Lymphoma
GWT-TUD GmbH 306
Next Page